The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by[…]
Latest Immunotherapy Treatments
Monoclonal Antibody Treatment was Found Not to be Effective on Pleural Mesothelioma
A phase II clinical trial comparing anetumab ravtansine to the chemotherapy drug vinorelbine did not have promising results for treating mesothelioma like researchers had hoped. Anetumab ravtansine is an immunotherapy drug that is a monoclonal antibody, which is an engineered antibody that can be used to fight cancer. Researchers found[…]
A Cancer Vaccine Could Potentially Help Mesothelioma Patients
Researchers are looking at a vaccine to maintain patient health after cancer treatment, which could be effective for mesothelioma in the future. The vaccine is specifically made for each patient based on the individual’s biology. The trial is currently being tested on head and neck cancer. It does not usually[…]
OT-101 Useful for COVID-19 and Cancers Like Mesothelioma
Researchers are looking at a new treatment for mesothelioma. It is a multimodal treatment (multiple treatments combined) consisting of the immunotherapy drug Keytruda and a new drug called OT-101. OT-101 is an antisense drug, which is a drug that blocks molecules that make certain proteins. The drug is also effective[…]
Tremelimumab and Durvalumab Combination Can Improve Mesothelioma Survival
Studies show that durvalumab and tremelimumab work very well together while treating mesothelioma. A phase I clinical trial was performed at the Baylor College of Medicine in conjunction with Baylor St. Luke’s Medical Center. Durvalumab is an immunotherapy drug known as a PD-1/PD-L1 checkpoint inhibitor. It works by blocking the[…]
The immunotherapy Drug Bevacizumab Can Improve Survival in Mesothelioma Patients
An immune system boosting therapy could potentially be used to treat mesothelioma. For a long period of time, chemotherapy drugs have been the standard drug to fight mesothelioma, but researchers believe bevacizumab could change this and be used alongside standard mesothelioma treatments. Chemotherapy is popular with doctors, but chemotherapy drugs[…]
Epigenetics Used to Improve Immunotherapy for Mesothelioma
Researchers are looking into changing mesothelioma cells to make them more susceptible to immunotherapy. Mesothelioma is a hard cancer to treat, so new approaches need to be developed to try to lengthen and improve mesothelioma patients’ lives. Immunotherapy can work well for some, but for others it does very little,[…]
UCARTMESO CAR-T Cell Therapy Can Help Kill Mesothelioma Cells
A new treatment utilizing CAR-T cell therapy could help prevent mesothelioma cells from protecting themselves. The treatment, called UCARTMESO, is being developed by the French biopharmaceutical company Cellectis. The treatment works by targeting cells that overexpress mesothelin, which is an antigen that prevents cells from sending immune suppressive signals. A[…]
Ramucirumab and Gemcitabine are Showing Promising Results as a Second Line Treatment for Pleural Mesothelioma
Combining the drug ramucirumab with the chemotherapy drug gemcitabine is showing to be a successful second line treatment for pleural mesothelioma. Ramucirumab is a type of immunotherapy drug called a monoclonal antibody, which targets and restricts proteins that stimulate blood vessel growth in tumors. The Lancet Oncology published the results[…]
CAR-T Cell Therapy and Keytruda is Showing Real Promise
Researchers at the Memorial Sloan Kettering Cancer Center are experimenting with a combination of CAR-T cell therapy and Keytruda, a PD-1 blocker for the treatment of pleural mesothelioma. This is the first time that these two therapies have been combined. The results were recently published in Cancer Discovery. Mesothelioma is[…]
